Moxifloxacin Hydrochloride and Sodium Chloride Injection
Product name: Moxifloxacin Hydrochloride and Sodium Chloride Injection(400mg/250ml)
contains the following:
| S. No. |
Ingredients |
Specification |
Quantity |
Function |
| A |
Moxifloxacin Hydrochloride |
In-house Standard |
0.4525g
(After being dried and purified, the actual content of moxifloxacin is 0.4g.) |
Active ingredient |
| B |
Sodium Chloride |
CP2015 |
2.0g |
Excipient |
| C |
Water for Injection |
CP2015 |
q.s. to 250ml |
Solvent |
The raw material in the prescription is moxifloxacin, and the actual material is Moxifloxacin Hydrochloride, pay attention to calculate the amount of dry Moxifloxacin.
Composition.
Indication: This product is suitable for the adult (age≥18 years) infective disease caused by sensitive bacteria.
-Community acquired pneumonia (CAP)
-Complicated skin and skin structure infections (cSSSI)
Shijiazhuang No.4 Pharmaceutical Co., Ltd. was established in 1948, now it is a large-sized foreign invested enterprise and comprehensive medicine manufacturer in China, the capital is USD58 million, and with more than 3000 employees. The company can manufacture 7 series medicines of more than 100 kinds and specifications including infusions, capsules, granules, tablets, oral liquids and etc with GMP approval by SFDA of China. For the key product of large volume I.V solution, the yearly output has reached more than 1200 million bottles including 40 million bottles packing with the soft plastic bottles in the dosage of 500 ml/ 250 ml /100ml. Some index such as quality, variety, and yearly output are all in the leading position of this field in China.
The products have been sold to some countries and regions in South America, Africa, and Asia.
Audited Supplier 
Shijiazhuang No.4 Pharmaceutical Co., Ltd. was established in 1948, now it is a large-sized foreign invested enterprise and comprehensive medicine manufacturer in China, the capital is USD58 million, and with more than 3000 employees. The company can manufacture 7 series medicines of more than 100 kinds and specifications including infusions, capsules, granules, tablets, oral liquids and etc with GMP approval by SFDA of China. For the key product of large volume I.V solution, the yearly output has reached more than 1200 million bottles including 40 million bottles packing with the soft plastic bottles in the dosage of 500 ml/ 250 ml /100ml. Some index such as quality, variety, and yearly output are all in the leading position of this field in China. 
){kind=link}
){kind=link}